Notes
CORRECTION to screen/ADCdb: ADCdb lists "Approved (FDA): Nov 2024", but this is actually China NMPA approval (Kelun-Biotech, 2024-11-27, 2L+ mTNBC; NSCLC added 2025). Sac-TMT is NOT FDA-approved; FDA granted only Breakthrough Therapy Designation (Dec 2024, EGFRm NSCLC). Recorded approval_status as "Approved (China NMPA)".
ANTIBODY: Sac-TMT shares the SAME anti-TROP2 antibody (sacituzumab/hRS7, humanized IgG1, identical sequence to IMMU-132) as sacituzumab govitecan already in the DB, but differs in payload (KL610023, a belotecan-derived TOP1 inhibitor vs SN-38) and linker (sulfonyl pyrimidine-CL2A-carbonate vs CL2A maleimide). DAR 7.4 (ADCdb "7 to 8"). Useful as a low-OAE TROP2 ADC comparator.
OCULAR (priority): Fully cross-verified by the dedicated Frontiers 2026 ADC ocular-toxicity review (fimmu.2026.1698458): OptiTROP-Breast01 (N=130, 5 mg/kg Q2W) xerophthalmia 2.3% (all G1-2), blurred vision 1.5% (all G1), no grade >=3; OptiTROP-Lung03 Part II (N=91) blurred vision + ophthalmodynia each ~1% (G1); KL264-01 one dry-eye case led to discontinuation among ~36 TNBC pts. oae_any_pct=2.3 = max PT (xerophthalmia) at RP2D. ocular_surface_subtype="Mixed" (dry eye = ocular surface + blurred vision = visual; no keratopathy/conjunctivitis).
PAYLOAD PHYSCHEM: KL610023 (T030) is not in PubChem by name; no KL610023-specific MW/XLogP3/logD/TPSA/pKa/charge retrievable from PubChem or the chemistry literature, so those cells left blank (conservative). Bystander effect = Yes (well documented, PMC9817100). Parent belotecan (PubChem CID 6456014: C25H27N3O4, MW 433.5, XLogP 1.6, TPSA 91.8) noted for context only; NOT substituted because KL610023 is a distinct derivative.
DOSING: 5 mg/kg IV Q2W (single infusion per cycle, not fractionated). The PMC review's "4 mg/kg" appears to be an extraction error; 5 mg/kg Q2W is corroborated by the ASCO abstract, Nature Medicine paper, and Frontiers ocular review.
TOXICITY caveats: Any-grade TRAEs are from the Nat Med 2025 / ASCO 2024 OptiTROP-Breast01 table (n=130, RP2D). Headline grade >=3 TRAEs: neutrophil 32.3%, anaemia 27.7%, WBC 25.4% (overall grade >=3 TRAE 57.7%). Breast01-specific grade >=3 values for thrombocytopenia/stomatitis/ALT/AST were not separately retrieved (left to any-grade rows). Pulmonary ILD and peripheral neuropathy rows entered as pct=0 (tier C) based on reported-absence statements (KL264-01/review), not Breast01 tabulations - both notable negatives for a TOP1 ADC. Rash (31%) and alopecia omitted (no matching organ_system enum). No infusion-reaction data retrieved (Infusion left blank). Linker_plasma_t_half=2.3 d derived from preclinical in vivo payload t1/2 56.3 h (PMC9817100; vs IMMU-132 15.5 h) - methodologically comparable to how govitecan's 0.7 was derived.